Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.

Cancer medicine - 1 Nov 2020

Jiang Junjie, Ding Yongfeng, Wu Mengjie, Chen Yanyan, Lyu Xiadong, Lu Jun, Wang Haiyong, Teng Lisong

Abstract excerpt

Several biomarkers such as tumor mutation burden (TMB), neoantigen load (NAL), programmed cell-death receptor 1 ligand (PD-L1) expression, and lactate dehydrogenase (LDH) have been developed for predicting response to immune checkpoint inhibitors (ICIs) in melanoma. However, some limitations including the undefined cut-off value, poor uniformity of test platform, and weak reliability of prediction have restricted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Decision Support Techniques
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunogenetic Phenomena

Share to Melanoma

Share to Predictive Value of Tests

Share to Progression-Free Survival

Share to Risk Assessment

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32969604
DOI: 10.1002/cam4.3481
PMCID: PMC7666739

Genes

NF1
SERPINB3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.PMID 32969604Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.Semantic proximity Read ↗

Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance MechanismsSemantic proximity Read ↗

A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy.Semantic proximity Read ↗

The immune response-related genomic alterations in patients with malignant melanoma.Semantic proximity Read ↗

Developing a prognostic model for skin melanoma based on the persistent tumor mutation burden and determining IL17REL as a therapeutic target.Semantic proximity Read ↗

Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.Semantic proximity Read ↗

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Gene expression and immune infiltration in melanoma patients with different mutation burden.Semantic proximity Read ↗

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response RatesSemantic proximity Read ↗

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer.Semantic proximity Read ↗

Bioinformatic and Machine Learning Applications in Melanoma Risk Assessment and Prognosis: A Literature Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.